PMID- 20040049
OWN - NLM
STAT- MEDLINE
DCOM- 20100830
LR  - 20171116
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 30
IP  - 3
DP  - 2010 Mar
TI  - Hepatitis C and diabetes: one treatment for two diseases?
PG  - 356-64
LID - 10.1111/j.1478-3231.2009.02185.x [doi]
AB  - Abstract Epidemiological data clearly indicate a link between chronic hepatitis C 
      (CHC) and disturbed glucose homeostasis. The prevalences of both type 2 diabetes 
      mellitus (T2DM) and insulin resistance (IR) are higher among those chronically 
      infected with hepatitis C when compared with the general population and those 
      with other causes of chronic liver disease. Both IR and diabetes are associated 
      with adverse outcomes across all stages of CHC including the liver transplant 
      population. The adverse effects that directly influence patient outcome are 
      reduced responsiveness to antiviral therapy, more rapid progression of fibrosis 
      to cirrhosis and a higher incidence of hepatocellular carcinoma. Although both 
      viral and host factors are known to contribute to IR (and therefore the risk of 
      T2DM), there is a paucity of evidence to support interventions targeting IR with 
      pharmacotherapy or lifestyle intervention. The purpose of this review is to 
      examine the impact of abnormalities of glucose homeostasis in CHC, and in so 
      doing, to raise a number of questions. How do we identify those at risk of 
      diabetes in CHC? Can we reduce the incidence of hepatoma and reduce 
      transplant-related morbidity and mortality by preventing or treating diabetes? 
      Can we improve the response to antiviral therapy by pretreating IR and T2DM in 
      treatment candidates? Ultimately, can we cure two diseases, diabetes and CHC, 
      with one treatment?
FAU - Pattullo, Venessa
AU  - Pattullo V
AD  - Division of Gastroenterology, Toronto Western Hospital, University Health 
      Network, University of Toronto, Toronto, ON, Canada.
FAU - Heathcote, Jenny
AU  - Heathcote J
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20091222
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Antiviral Agents)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Carcinoma, Hepatocellular/complications
MH  - Diabetes Mellitus, Type 2/drug therapy/metabolism/*virology
MH  - Glucose/metabolism
MH  - Glucose Tolerance Test
MH  - Hepatitis C, Chronic/*complications/metabolism/virology
MH  - Humans
MH  - Insulin Resistance
MH  - Liver Neoplasms/etiology
MH  - Metabolic Syndrome/complications
RF  - 82
EDAT- 2009/12/31 06:00
MHDA- 2010/08/31 06:00
CRDT- 2009/12/31 06:00
PHST- 2009/12/31 06:00 [entrez]
PHST- 2009/12/31 06:00 [pubmed]
PHST- 2010/08/31 06:00 [medline]
AID - LIV2185 [pii]
AID - 10.1111/j.1478-3231.2009.02185.x [doi]
PST - ppublish
SO  - Liver Int. 2010 Mar;30(3):356-64. doi: 10.1111/j.1478-3231.2009.02185.x. Epub 
      2009 Dec 22.